Targeting CD133 reverses drug-resistance via the AKT/NF-kappaB/MDR1 pathway in colorectal cancer. Yuan Z, Liang X, Zhan Y, Wang Z, et al. Br J Cancer 2020 Mar 16. pii: 10.1038/s41416-020-0783.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yuan Z, Liang X, Zhan Y, Wang Z, et al. Targeting CD133 reverses drug-resistance via the AKT/NF-kappaB/MDR1 pathway in colorectal cancer. Br J Cancer 2020 Mar 16. pii: 10.1038/s41416-020-0783.
PMID: 32203206